Cargando…

What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis

INTRODUCTION: To determine patient and rheumatologist preferences for rheumatoid arthritis (RA) treatment attributes in Spain and to evaluate their attitude towards shared decision-making (SDM). METHODS: Observational, descriptive, exploratory and cross-sectional study based on a discrete choice exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz-Torné, Cesar, Urruticoechea-Arana, Ana, Ivorra-Cortés, José, Díaz, Silvia, Dilla, Tatiana, Sacristán, José Antonio, Inciarte-Mundo, José, Comellas, Marta, Prades, Miriam, Lizán, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140752/
https://www.ncbi.nlm.nih.gov/pubmed/32088860
http://dx.doi.org/10.1007/s12325-020-01258-5
_version_ 1783519062637150208
author Díaz-Torné, Cesar
Urruticoechea-Arana, Ana
Ivorra-Cortés, José
Díaz, Silvia
Dilla, Tatiana
Sacristán, José Antonio
Inciarte-Mundo, José
Comellas, Marta
Prades, Miriam
Lizán, Luis
author_facet Díaz-Torné, Cesar
Urruticoechea-Arana, Ana
Ivorra-Cortés, José
Díaz, Silvia
Dilla, Tatiana
Sacristán, José Antonio
Inciarte-Mundo, José
Comellas, Marta
Prades, Miriam
Lizán, Luis
author_sort Díaz-Torné, Cesar
collection PubMed
description INTRODUCTION: To determine patient and rheumatologist preferences for rheumatoid arthritis (RA) treatment attributes in Spain and to evaluate their attitude towards shared decision-making (SDM). METHODS: Observational, descriptive, exploratory and cross-sectional study based on a discrete choice experiment (DCE). To identify the attributes and their levels, a literature review and two focus groups (patients [P] = 5; rheumatologists [R] = 4) were undertaken. Seven attributes with 2–4 levels were presented in eight scenarios. Attribute utility and relative importance (RI) were assessed using a conditional logit model. Patient preferences for SDM were assessed using an ad hoc questionnaire. RESULTS: Ninety rheumatologists [52.2% women; mean years of experience 18.1 (SD: 9.0); seeing an average of 24.4 RA patients/week (SD: 15.3)] and 137 RA patients [mean age: 47.5 years (SD: 10.7); 84.0% women; mean time since diagnosis of RA: 14.2 years (SD: 11.8) and time in treatment: 13.2 years (SD: 11.2), mean HAQ score 1.2 (SD: 0.7)] participated in the study. In terms of RI, rheumatologists and RA patients viewed: time with optimal QoL: R: 23.41%/P: 35.05%; substantial symptom improvement: R: 13.15%/P: 3.62%; time to onset of treatment action: R: 16.24%/P: 13.56%; severe adverse events: R: 10.89%/P: 11.20%; mild adverse events: R: 4.16%/P: 0.91%; mode of administration: R: 25.23%/P: 25.00%; and added cost: R: 6.93%/P: 10.66%. Nearly 73% of RA patients were involved in treatment decision-making to a greater or lesser extent; however, 27.4% did not participate at all. CONCLUSION: Both for rheumatologists and patients, the top three decision-making drivers are time with optimal quality, treatment mode of administration and time to onset of action, although in different ranking order. Patients were willing to be more involved in the treatment decision-making process. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12325-020-01258-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7140752
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-71407522020-04-14 What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis Díaz-Torné, Cesar Urruticoechea-Arana, Ana Ivorra-Cortés, José Díaz, Silvia Dilla, Tatiana Sacristán, José Antonio Inciarte-Mundo, José Comellas, Marta Prades, Miriam Lizán, Luis Adv Ther Original Research INTRODUCTION: To determine patient and rheumatologist preferences for rheumatoid arthritis (RA) treatment attributes in Spain and to evaluate their attitude towards shared decision-making (SDM). METHODS: Observational, descriptive, exploratory and cross-sectional study based on a discrete choice experiment (DCE). To identify the attributes and their levels, a literature review and two focus groups (patients [P] = 5; rheumatologists [R] = 4) were undertaken. Seven attributes with 2–4 levels were presented in eight scenarios. Attribute utility and relative importance (RI) were assessed using a conditional logit model. Patient preferences for SDM were assessed using an ad hoc questionnaire. RESULTS: Ninety rheumatologists [52.2% women; mean years of experience 18.1 (SD: 9.0); seeing an average of 24.4 RA patients/week (SD: 15.3)] and 137 RA patients [mean age: 47.5 years (SD: 10.7); 84.0% women; mean time since diagnosis of RA: 14.2 years (SD: 11.8) and time in treatment: 13.2 years (SD: 11.2), mean HAQ score 1.2 (SD: 0.7)] participated in the study. In terms of RI, rheumatologists and RA patients viewed: time with optimal QoL: R: 23.41%/P: 35.05%; substantial symptom improvement: R: 13.15%/P: 3.62%; time to onset of treatment action: R: 16.24%/P: 13.56%; severe adverse events: R: 10.89%/P: 11.20%; mild adverse events: R: 4.16%/P: 0.91%; mode of administration: R: 25.23%/P: 25.00%; and added cost: R: 6.93%/P: 10.66%. Nearly 73% of RA patients were involved in treatment decision-making to a greater or lesser extent; however, 27.4% did not participate at all. CONCLUSION: Both for rheumatologists and patients, the top three decision-making drivers are time with optimal quality, treatment mode of administration and time to onset of action, although in different ranking order. Patients were willing to be more involved in the treatment decision-making process. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12325-020-01258-5) contains supplementary material, which is available to authorized users. Springer Healthcare 2020-02-22 2020 /pmc/articles/PMC7140752/ /pubmed/32088860 http://dx.doi.org/10.1007/s12325-020-01258-5 Text en © Springer Healthcare Ltd., part of Springer Nature 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Díaz-Torné, Cesar
Urruticoechea-Arana, Ana
Ivorra-Cortés, José
Díaz, Silvia
Dilla, Tatiana
Sacristán, José Antonio
Inciarte-Mundo, José
Comellas, Marta
Prades, Miriam
Lizán, Luis
What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis
title What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis
title_full What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis
title_fullStr What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis
title_full_unstemmed What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis
title_short What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis
title_sort what matters most to patients and rheumatologists? a discrete choice experiment in rheumatoid arthritis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140752/
https://www.ncbi.nlm.nih.gov/pubmed/32088860
http://dx.doi.org/10.1007/s12325-020-01258-5
work_keys_str_mv AT diaztornecesar whatmattersmosttopatientsandrheumatologistsadiscretechoiceexperimentinrheumatoidarthritis
AT urruticoecheaaranaana whatmattersmosttopatientsandrheumatologistsadiscretechoiceexperimentinrheumatoidarthritis
AT ivorracortesjose whatmattersmosttopatientsandrheumatologistsadiscretechoiceexperimentinrheumatoidarthritis
AT diazsilvia whatmattersmosttopatientsandrheumatologistsadiscretechoiceexperimentinrheumatoidarthritis
AT dillatatiana whatmattersmosttopatientsandrheumatologistsadiscretechoiceexperimentinrheumatoidarthritis
AT sacristanjoseantonio whatmattersmosttopatientsandrheumatologistsadiscretechoiceexperimentinrheumatoidarthritis
AT inciartemundojose whatmattersmosttopatientsandrheumatologistsadiscretechoiceexperimentinrheumatoidarthritis
AT comellasmarta whatmattersmosttopatientsandrheumatologistsadiscretechoiceexperimentinrheumatoidarthritis
AT pradesmiriam whatmattersmosttopatientsandrheumatologistsadiscretechoiceexperimentinrheumatoidarthritis
AT lizanluis whatmattersmosttopatientsandrheumatologistsadiscretechoiceexperimentinrheumatoidarthritis